Odyssey Health (ODYY) Cash from Financing Activities (2014 - 2026)
Odyssey Health's (ODYY) quarterly Cash from Financing Activities came in at $875000.0 in Q1 2026, up 201.2% quarter-over-quarter from $290500.0 in Q4 2025.
Odyssey Health (ODYY) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Odyssey Health's Cash from Financing Activities history runs 13 years deep, the most recent figure standing at $875000.0 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $875000.0 in Q1 2026; TTM through Apr 2026 was $1.2 million, a 286.6% increase from a year earlier, with the FY2025 full-year figure at $294310.0, up 62.85% from the prior year.
- Cash from Financing Activities advanced to $875000.0 in Q1 2026 per ODYY's latest filing, from $290500.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $1.1 million in Q2 2022 and bottomed at -$860659.0 in Q3 2022.
- The 5-year median for Cash from Financing Activities is $189212.0 (2023), against an average of $247067.4.
- Across the five-year window, Cash from Financing Activities surged 611.35% in 2023 and plunged 113.97% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at $270710.0 in 2022, then retreated by 18.39% to $220924.0 in 2023, then soared by 35.79% to $300000.0 in 2024, then retreated by 3.17% to $290500.0 in 2025, then jumped by 201.2% to $875000.0 in 2026.
- Per Business Quant, the three latest ODYY Cash from Financing Activities figures stand at $875000.0 (Q1 2026), $290500.0 (Q4 2025), and -$5690.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Odyssey Health | 1.08 Mn | 782,508.17 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 875,000.00 |
| Jan 31, 2026 | 875,000.00 |
| Oct 31, 2025 | 290,500.00 |
| Oct 31, 2025 | 290,500.00 |
| Jul 31, 2025 | -5,690.00 |
| Jul 31, 2025 | -5,690.00 |
| Oct 31, 2024 | 300,000.00 |
| Oct 31, 2024 | 300,000.00 |
| Apr 30, 2024 | 84,007.00 |
| Apr 30, 2024 | 84,007.00 |
| Jan 31, 2024 | -124,207.00 |
| Jan 31, 2024 | -124,207.00 |
| Oct 31, 2023 | 220,924.00 |
| Oct 31, 2023 | 220,924.00 |
| Jul 31, 2023 | 157,500.00 |
| Jul 31, 2023 | 157,500.00 |
| Apr 30, 2023 | 131,690.00 |
| Apr 30, 2023 | 131,690.00 |
| Jan 31, 2023 | 889,188.00 |
| Jan 31, 2023 | 889,188.00 |